• 1
    Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 115661
  • 2
    Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 98190
  • 3
    Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 6670
  • 4
    Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 13208
  • 5
    Schroder FH, Denis L, Roobol MJ. Epilogue: different approaches for prostate cancer screening in the EU? Eur J Cancer 2010; 46: 31205
  • 6
    Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008; 54: 27490
  • 7
    Roobol MJ, van Vugt HA, Loeb S et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012; 61: 57783
  • 8
    Kranse R, Roobol M, Schroder FH. A graphical device to represent the outcomes of a logistic regression analysis. Prostate 2008; 68: 167480
  • 9
    Roobol MJ, Kirkels WJ, Schroder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 2003; 92 (Suppl. 2): 4854
  • 10
    Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199202; discussion 202–3
  • 11
    Chou R, Croswell JM, Dana T et al. Screening for prostate cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med 2011; 155: 76271
  • 12
    Moyer VA, on behalf of the USPSTF. Screening for Prostate Cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 12034
  • 13
    Djulbegovic M, Beyth RJ, Neuberger MM et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341: c4543
  • 14
    Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schroder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 1104
  • 15
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 28994
  • 16
    Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58: 4116
  • 17
    Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 223946
  • 18
    Raaijmakers R, Blijenberg BG, Finlay JA et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 2004; 171: 22459
  • 19
    van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003; 95: 14626
  • 20
    Zhu X, van Leeuwen PJ, Bul M et al. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up. Eur Urol 2011; 60: 3306
  • 21
    Otto SJ, Moss SM, Maattanen L et al. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer 2010; 46: 305360
  • 22
    Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ. Risk-based prostate cancer screening. Eur Urol 2012; 61: 65261
  • 23
    Hoeks CM, Barentsz JO, Hambrock T et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261: 4666
  • 24
    Hoeks CM, Schouten MG, Bomers JG et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012; [Epub ahead of print]
  • 25
    Schröder FH, van den Bergh RC, Wolters T et al. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol 2010; 57: 25866
  • 26
    Garzotto M, Hudson RG, Peters L et al. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer 2003; 98: 141722
  • 27
    Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med 2009; 60: 13951
  • 28
    Cavadas V, Osorio L, Sabell F, Teves F, Branco F, Silva-Ramos M. Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol 2010; 58: 5518
  • 29
    Trottier G, Roobol MJ, Lawrentschuk N et al. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int 2011; 108: E23744
  • 30
    Alibhai SM, Krahn MD, Fleshner NE, Cohen MM, Tomlinson GA, Naglie G. The association between patient age and prostate cancer stage and grade at diagnosis. BJU Int 2004; 94: 3036
  • 31
    Cremers RG, Karim-Kos HE, Houterman S et al. Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989–2006. Eur J Cancer 2010; 46: 207787
  • 32
    Boevee SJ, Venderbos LD, Tammela TL et al. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. Eur J Cancer 2010; 46: 30829
  • 33
    Gosselaar C, Roobol MJ, Roemeling S et al. Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Prostate 2006; 66: 62531
  • 34
    Gosselaar C, Roobol MJ, van den Bergh RC, Wolters T, Schroder FH. Digital rectal examination and the diagnosis of prostate cancer–a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Eur Urol 2009; 55: 13946